Clinical Trial: Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)

U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06974344) titled 'Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)' on April 15.

Brief Summary: The goal of this clinical trial is to compare two treatments for regulating blood flow in small liver grafts during living donor liver transplantation (LDLT). The main questions it aims to answer are:

* Is octreotide (a medication) as effective or better than splenic artery ligation (surgery) in reducing complications after transplantation?

* Which treatment better controls blood flow while causing fewer side effects?

Researchers will compare octreotide (given through an IV) to splenic art...